Joziasse D H, Lee R T, Lee Y C, Biessen E A, Schiphorst W E, Koeleman C A, van den Eijnden D H
Department of Medical Chemistry, Vrije Universiteit, Amsterdam, the Netherlands.
Eur J Biochem. 2000 Nov;267(21):6501-8. doi: 10.1046/j.1432-1327.2000.01747.x.
In mammals, clearance of desialylated serum glycoproteins to the liver is mediated by a galactose-specific hepatic lectin, the 'asialoglycoprotein receptor'. In humans, serum glycoprotein glycans are usually capped with sialic acid, which protects these proteins against hepatic uptake. However, in most other species, an additional noncharged terminal element with the structure Galalpha1-->3Galbeta1-->4R is present on glycoprotein glycans. To investigate if alpha3-galactosylated glycoproteins, just like desialylated glycoproteins, could be cleared by the hepatic lectin, the affinities of alpha3-galactosylated compounds towards this lectin were determined using an in vitro inhibition assay, and were compared with those of the parent compounds terminating in Galbeta1-->4R. Diantennary, triantennary and tetraantennary oligosaccharides that form part of N-glycans were alpha3-galactosylated to completion by use of recombinant bovine alpha3-galactosyltransferase. Similarly, desialylated alpha1-acid glycoprotein (orosomucoid) was alpha3-galactosylated in vitro. The alpha3-galactosylation of a branched, Galbeta1-->4-terminated oligosaccharide lowered its affinity for the membrane-bound lectin on whole rat hepatocytes 50-250-fold, and for the detergent-solubilized hepatic lectin 7-50-fold. In contrast, alpha3-galactosylation of asialo-alpha1-acid glycoprotein caused only a minor decrease in affinity, increasing the IC50 from 5 to 15 nM. Fully alpha3-galactosylated alpha1-acid glycoprotein, intravenously injected into the mouse, was rapidly cleared from the circulation, with a clearance rate close to that of asialo-alpha1-acid glycoprotein (t1/2 of 0.42 min vs. 0.95 min). Its uptake was efficiently inhibited by pre-injection of an excess asialo-fetuin. Organ distribution analysis showed that the injected alpha1-acid glycoprotein accumulated predominantly in the liver. Taken together, these observations suggest that serum glycoproteins that are heavily alpha3-galactosylated will be rapidly cleared from the bloodstream via the hepatic lectin. It is suggested that glycosyltransferase expression in murine hepatocytes is tightly regulated in order to prevent undesired uptake of hepatocyte-derived, circulating glycoproteins.
在哺乳动物中,去唾液酸化血清糖蛋白向肝脏的清除是由一种半乳糖特异性肝凝集素——“去唾液酸糖蛋白受体”介导的。在人类中,血清糖蛋白聚糖通常被唾液酸封端,这可保护这些蛋白质不被肝脏摄取。然而,在大多数其他物种中,糖蛋白聚糖上存在一种额外的不带电荷的末端元件,其结构为Galα1→3Galβ1→4R。为了研究α3-半乳糖基化糖蛋白是否像去唾液酸化糖蛋白一样能被肝凝集素清除,使用体外抑制试验测定了α3-半乳糖基化化合物对该凝集素的亲和力,并与以Galβ1→4R结尾的母体化合物的亲和力进行了比较。通过使用重组牛α3-半乳糖基转移酶,将构成N-聚糖一部分的二天线、三天线和四天线寡糖完全α3-半乳糖基化。同样,去唾液酸化的α1-酸性糖蛋白(血清类黏蛋白)在体外也被α3-半乳糖基化。一个分支的、以Galβ1→4结尾的寡糖的α3-半乳糖基化使其对全大鼠肝细胞上膜结合凝集素的亲和力降低了50-250倍,对去污剂溶解的肝凝集素的亲和力降低了7-50倍。相比之下,去唾液酸-α1-酸性糖蛋白的α3-半乳糖基化仅导致亲和力略有下降,IC50从5 nM增加到15 nM。静脉注射到小鼠体内的完全α3-半乳糖基化的α1-酸性糖蛋白迅速从循环中清除,清除率接近去唾液酸-α1-酸性糖蛋白(半衰期分别为0.42分钟和0.95分钟)。预先注射过量的去唾液酸胎球蛋白可有效抑制其摄取。器官分布分析表明,注射的α1-酸性糖蛋白主要在肝脏中积累。综上所述,这些观察结果表明,高度α3-半乳糖基化的血清糖蛋白将通过肝凝集素从血液中迅速清除。有人提出,小鼠肝细胞中糖基转移酶的表达受到严格调控,以防止肝细胞来源的循环糖蛋白被意外摄取。